These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33559013)

  • 1. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
    Fazio N; Abdel-Rahman O
    Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: Mayo Clinic Experience.
    Gile JJ; Liu AJ; McGarrah PW; Eiring RA; Hobday TJ; Starr JS; Sonbol MB; Halfdanarson TR
    Pancreas; 2021 Apr; 50(4):500-505. PubMed ID: 33939660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
    Xu G; Wang Y; Zhang H; She X; Yang J
    Future Oncol; 2021 Mar; 17(9):1069-1081. PubMed ID: 33136448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
    Barroso-Sousa R; Tolaney SM
    Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
    Mohamed A; Azmi AS; Asa SL; Tirumani SH; Mahipal A; Cjakrabarti S; Bajor D; Selfridge JE; Kaseb AO
    Curr Oncol; 2022 Nov; 29(11):9018-9030. PubMed ID: 36421360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Present and future of immunotherapy in Neuroendocrine Tumors".
    Albertelli M; Dotto A; Nista F; Veresani A; Patti L; Gay S; Sciallero S; Boschetti M; Ferone D
    Rev Endocr Metab Disord; 2021 Sep; 22(3):615-636. PubMed ID: 33851319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment personalization in gastrointestinal neuroendocrine tumors.
    Borga C; Businello G; Murgioni S; Bergamo F; Martini C; De Carlo E; Trevellin E; Vettor R; Fassan M
    Curr Treat Options Oncol; 2021 Feb; 22(4):29. PubMed ID: 33641005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
    Weber MM; Fottner C
    Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
    Cives M; Strosberg J
    Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
    Pelster MS; Amaria RN
    Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
    Grisay G; Pierrard J; Confente C; Seront E
    Curr Treat Options Oncol; 2020 Dec; 22(1):7. PubMed ID: 33269438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.
    Yue S; Zhang Y; Zhang W
    Curr Treat Options Oncol; 2024 Aug; 25(8):1089-1111. PubMed ID: 39066855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
    Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
    BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review.
    Regalla DKR; Deep O; Paluri RK
    Chin Clin Oncol; 2023 Dec; 12(6):67. PubMed ID: 38073310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in immunotherapy for neuroendocrine neoplasm of the digestive system.
    Pan WX; Zhang XM; Hao SL; Han W
    World J Gastroenterol; 2023 Jul; 29(26):4174-4185. PubMed ID: 37475845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.
    Oronsky B; Ma PC; Morgensztern D; Carter CA
    Neoplasia; 2017 Dec; 19(12):991-1002. PubMed ID: 29091800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.
    Sonbol MB; Halfdanarson TR
    Curr Treat Options Oncol; 2019 Aug; 20(9):74. PubMed ID: 31428952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
    J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
    Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
    Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.